286 related articles for article (PubMed ID: 15732339)
1. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
3. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
[TBL] [Abstract][Full Text] [Related]
4. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
5. [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis].
Uphoff J; Woziwodzki J; Schattka SO; Kollias A
Aktuelle Urol; 2008 Sep; 39(5):373-7. PubMed ID: 18798127
[TBL] [Abstract][Full Text] [Related]
6. [A case of poorly differentiated adenocarcinoma of prostate with neuroendocrine differentiation].
Miyoshi Y; Inoue Y; Matsuzaki J; Fukuda M; Satomi Y; Akahane H; Saito S
Hinyokika Kiyo; 1998 Feb; 44(2):113-6. PubMed ID: 9546133
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation in adenocarcinoma of the prostate with progression of disease during hormonal treatment: a report of two cases].
Kosugi M; Hanawa Y; Momma T; Saito S; Hirose S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):521-4. PubMed ID: 12795167
[TBL] [Abstract][Full Text] [Related]
8. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
9. [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
Kawahara T; Manabe Y; Asazuma A; Aoyama T; Hashimura T
Hinyokika Kiyo; 2009 Oct; 55(10):627-9. PubMed ID: 19938335
[TBL] [Abstract][Full Text] [Related]
10. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
11. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
12. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
13. [Endometrioid adenocarcinoma of the prostate: report of 3 cases].
Uemura M; Nakagawa M; Kanno N; Nishimura K; Miyoshi S; Kawano K
Hinyokika Kiyo; 2004 Nov; 50(11):825-8. PubMed ID: 15628548
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine cells in the prostatic carcinomas after neoadjuvant hormonal therapy.
Chen X; Okada H; Gotoh A; Arakawa S; Kamidono S
Kobe J Med Sci; 1997 Apr; 43(2):71-81. PubMed ID: 9385786
[TBL] [Abstract][Full Text] [Related]
18. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
19. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy.
Azad AA; Jones EC; Chi KN
Clin Genitourin Cancer; 2014 Aug; 12(4):e151-3. PubMed ID: 24787970
[No Abstract] [Full Text] [Related]
20. [Studies of progressive factors of stage A prostatic cancer].
Suzuki T; Shimizu T; Imai K; Yamanaka H; Suzuki K; Takahashi H
Hinyokika Kiyo; 1989 Feb; 35(2):259-63. PubMed ID: 2735237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
